AU2004270069A1 - Oral Itraconazole Composition Which is Not Affected by Ingested Food and Process for Preparing Same - Google Patents
Oral Itraconazole Composition Which is Not Affected by Ingested Food and Process for Preparing Same Download PDFInfo
- Publication number
- AU2004270069A1 AU2004270069A1 AU2004270069A AU2004270069A AU2004270069A1 AU 2004270069 A1 AU2004270069 A1 AU 2004270069A1 AU 2004270069 A AU2004270069 A AU 2004270069A AU 2004270069 A AU2004270069 A AU 2004270069A AU 2004270069 A1 AU2004270069 A1 AU 2004270069A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- itraconazole
- ingestion
- surfactant
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 67
- 229960004130 itraconazole Drugs 0.000 title claims description 63
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title claims description 62
- 235000013305 food Nutrition 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 26
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- 230000037406 food intake Effects 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 15
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 230000000996 additive effect Effects 0.000 claims description 13
- 239000002535 acidifier Substances 0.000 claims description 12
- -1 polyoxyethylene Polymers 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000011732 tocopherol Substances 0.000 claims description 8
- 229960001295 tocopherol Drugs 0.000 claims description 7
- 239000004530 micro-emulsion Substances 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 35
- 239000007902 hard capsule Substances 0.000 description 26
- 239000002775 capsule Substances 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 16
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 13
- 229940063138 sporanox Drugs 0.000 description 12
- 239000004359 castor oil Substances 0.000 description 11
- 235000019438 castor oil Nutrition 0.000 description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000008389 polyethoxylated castor oil Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 7
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000435809 Sarea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
WO 2005/023262 PCT/KR2004/002264 1 ORAL ITRACONAZOLE COMPOSITION WHICH IS NOT AFFECTED BY INGESTED FOOD AND PROCESS FOR PREPARING SAME FIELD OF THE INVENTION 5 The present invention relates to an oral composition of itraconazole having improved itraconazole bioavailability which is not affected by ingested food, and a process for the preparation thereof. 10 BACKGROUND OF THE INVENTION Itraconazole, a triazole compound, is known to have excellent antifungal activity. However, the bioavailability of orally administered itraconazole is very low because it has an exceedingly low solubility of less 15 than 1 tg/ml in water and it remains unionized in the gastric juice due to its pKa value of 3.7. Further, it is known that the degree of bioavailability of orally administered itraconazole varies widely among individuals and depends on other factors such as ingested foods. PCT International Publication No. WO 85/02767 and U.S. Patent No. 20 4,764,604 teach a method for increasing the solubility of itraconazole by employing a cyclodextrin inclusion compound of itraconazole. However, this method has the problems that the incremental increase in the itraconazole solubility is only marginal and various complicated preparative procedures are required. 25 PCT International Publication No. WO 94/05263 discloses a coated bead preparation, wherein a core made of pharmaceutically inert or neutral sucrose, dextrine, starch and the like is coated with a mixture of itraconazole and a hydrophilic polymer and, then, the resulting bead is coated again with a polymer, e.g., polyethylene glycol. Such a coated bead preparation is 30 conummercially available from Janssen Pharmaceutica(Beerse, Belgium) under the trade name of Sporanox capsule. However, the manufacturing process of the above preparation is very complicated due to the fact the beads having an average size of only 600 to 700 pm tend to undergo agglomeration during the manufacturing process. In addition, the itraconazole bioavailability of this 35 preparation varies widely depending on whether it is taken before or after food ingestion.
WO 2005/023262 PCT/KR2004/002264 2 PCT International Publication No. WO 97/44014 teaches a solid dispersion of itraconazole in a water-soluble polymer, which is prepared by subjecting a mixture of itraconazole and the water-soluble polymer to a melt-extrusion process at a temperature ranging from 245 IC to 265 °C. This 5 solid dispersion is described to have an improved bioavailability of itraconazole which is not influenced by ingested foods, and it is commercially available from Janssen Pharmaceutica(Beerse, Belgium) under the trade name of Sporanox® tablet. However, the manufacturing process of the solid dispersion is hampered by a number of difficulties in controlling various 10 process variables, and the in vivo bioavailability of itraconazole achievable with the above dispersion is still low. Sporanox ® liquid of pH 2, which is prepared by mixing a hydroxypropyl- 13 -cyclodextrin inclusion compound of itraconazole, hydrochloric acid, propylene glycol, purified water, sodium hydroxide, sodium 15 saccharin and sorbitol, and is commercially available from Janssen Pharmaceutica(Beerse, Belgium), exhibits a high bioavailability of itraconazole when administered before ingestion, but it has the problems that it must be taken in great quantities due to its low itraconazole concentration of 10 mg/ml, the active ingredient rapidly precipitates when it comes in contact with the 20 intestinal juice, and it is effective only against fumgus infection of esophagus. Recently, PCT International Publication No. WO 98/55148 discloses a high viscosity composition comprising a drug which has a very low solubility in water, cyclodextrin, water-soluble acid and a water-soluble organic polymer. However, this composition has a high viscosity, and accordingly, a large 25 amount of a dispersant is used to lower the viscosity during the capsule making process. In addition, the composition exhibits a very low dissolution rate of less than 1% under a neutral or alkaline condition of pH 6.8 or higher. In this regard, the present inventors suggested a micro-emulsion preconcentrate comprising an antiviral agent which has a very low solubility 30 in water, phosphoric acid, a co-surfactant, a surfactant and an oil in Korean Application No. 2000-83717, and further suggested another micro-emulsion composition modified based on said preconcentrate in Korean Application No. 2001-36930. However, these compositions still exhibit unsatisfactory itraconazole dissolution rates under a neutral or alkaline condition of pH 6.8 35 or higher, and thus their bioavailabilities of itraconazole more or less depend on ingested food.
WO 2005/023262 PCT/KR2004/002264 3 SUMMARY OF THE INVENTION It is, therefore, a primary object of the present invention to provide an 5 oral composition of itraconazole having improved itraconazole bioavailability which is little influenced by ingested food. It is a further object of the present invention to provide a process for preparing said oral composition. In accordance with one aspect of the present invention, there is provided 10 a viscous and glassy composition for oral administration comprising itraconazole, an acidifying agent, an amphiphilic additive, a surfactant and an oil. In accordance with another aspect of the present invention, there is provided a method of preparing said composition which comprises the steps of: 15 (a) dissolving itraconazole uniformly in a mixture of the acidifying agent, the amphiphilic additive and a volatile solvent, (b) dissolving the surfactant and the oil in the resulting solution, and (c) removing the volatile solvent therefrom. BRIEF DESCRIPTION OF THE DRAWINGS 20 The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawing, FIG. 1, which shows the respective itraconazole bioavailabilities of the preparations prepared in 25 Example 1 and Comparative Example before and after food ingestion. DETAILED DESCRIPTION OF THE INVENTION The inventive composition comprising itraconazole as an active 30 ingredient may be prepared using the other following components: (1) Acidifying agent Representative examples of the acidifying agent which may be used in the present invention to dissolve itraconazole include phosphoric acid, acetic acid, hydrochloric acid, nitric acid, sulfuric acid, citric acid, fumarie acid, 35 maleic acid, and an aqueous solution thereof, wherein 85% phosphoric acid or a diluted solution thereof is preferred.
WO 2005/023262 PCT/KR2004/002264 4 (2) Amphiphilic additive The amphiphilie additive which is used in the present invention serves to dissolve itraconazole and adjust the viscosity of the composition to a degree suitable for filling into a capsule. Suitable amphiphilic additives that may be 5 used in the present invention include transcutol(diethyleneglycol monoethyl ether, Gattefosse), dimethyl isosorbide(1,4:3,6-dianhydro-2,5-dimethyl-D glucitol), glycofurol(tetrahydrofurfuryl alcohol polyethylene glycol ether), propylene glycol(1,2-dihydroxypropane), propylene carbonate(4-methyl-2 oxo-1,3-dioxolane), solutol(macrogol 15 hydroxystearate, BASF) and a 10 mixture thereof, wherein transcutol is preferred. (3) Volatile solvent The volatile solvent employed during the manufacturing process, but not present in the final product, assists the dissolution of itraconazole by the action of the acidifying agent. In the present invention, preferably used as the 15 volatile solvent is a non-toxic organic solvent such as an alcohol, e.g., ethanol, propanol and isopropanol, which can be easily volatilized at a temperature of less than 100 C. (4) Surfactant The surfactant used in the present invention assists the formulation of a 20 uniform emulsion of an oil and hydrophilic components, and keeps the emulsion stable during storage. Representative examples of the surfactant include: (D polyoxyethylene glycolated natural or hydrogenated vegetable oils such as polyoxyethylene glycolated natural or hydrogenated castor 25 oil(Cremophor®, BASF; HCOO, Nikkol), () polyoxyethylene-sorbitan-fatty acid esters wherein fatty acid is mono- or tri-lauric, palmitic, stearic or oleic acid(Tween®, ICI), and () polyoxyethylene fatty acid esters such as polyoxyethylene stearic acid ester(Myrj, ICI). 30 (5) Oil The oil component used in the present invention should be compatible with the surfactant and capable of forming a stable microemulsion in an aqueous medium. It may be one of the pharmaceutically acceptable oils such as tocopherols and derivatives thereof including tocopheryl acetate, tocopheryl 35 succinate, and polyethyleneglycol-1000-tocopheryl succinate(TPGS).
WO 2005/023262 PCT/KR2004/002264 5 The inventive composition is prepared by (a) dissolving itraconazole in a mixture of the acidifying agent, the amphiphilic additive and the volatile solvent, (b) dissolving the surfactant and the oil in the resulting solution, and (c) removing the volatile solvent from the resulting mixed solution. 5 In step (c), the volatile solvent may be removed by the conventional method, e.g., by heating under the ambient pressure or a vacuum, preferably at a temperature ranging from 40 to 100 C, more preferably at a temperature ranging from 40 to 80 1C. In the above manufacturing process, itraconazole, the acidifying agent, 10 the amphiphilic additive, the volatile solvent, the surfactant and the oil are used in amounts corresponding to a weight ratio in the range of 1 : 0.5~15 : 0.5-20: 0.5-20 : 0.5-15 : 0.5-15, preferably 1 : 1~10: 1-15: 1-15 : 1~10: 1~10. The final composition of the present invention with the absence of volatile solvent comprises itraconazole, the acidifying agent, the amphiphilic 15 additive, the surfactant and the oil in a weight ratio in the range of 1 : 0.5-15: 0.5-20 : 0.5~15 : 0.5~15, preferably 1 : 1-10 : 1-15: 1~10: 1~10. In addition, the inventive composition may comprise pharmaceutically acceptable additives for oral administration such as anti-oxidants. 20 The pharmaceutical composition of the present invention may be formulated to obtain various pharmaceutical preparations, e.g., a powder, granule, tablet, coated preparation and liquid preparation, in accordance with any of the conventional procedures. For instance, a hard capsule may be prepared by adding a lubricant and other pharmaceutical additives to the 25 pharmaceutical composition, processing the mixture into a powder or granule and filling the powder or granule into a hard gelatin capsule; a tablet, by adding a suitable additive to the pharmaceutical composition and tableting the mixture; a liquid preparation, by dissolving the pharmaceutical composition in water; and a coated preparation, by coating a solution of the pharmaceutical 30 composition on a sugar bead such as Non-pareil ® (Edward Mendell Co., UK). The inventive itraconazole composition prepared is transparent and glassy, i.e., it has no fluidity, and has a high viscosity of at least 10,000 cps at 25 1C. This is achievable by the combined action of the amphiphilic additive and the volatile solvent used in the inventive method. The high viscosity 35 glassy composition is much more compact as compared with a conventional microemulsion composition.
WO 2005/023262 PCT/KR2004/002264 6 The inventive composition has self-microemulsifying capability to form high stable and available microemulsion particles when orally administered in the body fluid. Therefore, as the inventive composition can maintain a high and stable level of itraconazole dissolution rate even under a neutral or alkaline 5 condition of pH 6.8 or higher, the itraconazole bioavailability thereof is little influenced by ingested food; the itraconazole bioavailabilities of the inventive composition before and after ingestion are the same, the ratio of AUCbefore ingeson and AUCafter ingestion being close to 1 (AUC : area under the curve of blood concentration), preferably 0.8 or higher. 10 The following Examples are intended to further illustrate the present invention without limiting its scope. Further, percentages given below for solid in solid mixture, liquid in liquid, and solid in liquid are on a wt/wt, vol/vol and wt/vol basis, respectively, unless specifically indicated otherwise. 15 Example 1: Preparation of Hard Capsule -1) A hard capsule was prepared using the following ingredients: Quantitv(mg/capsule) 20 Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated 25 castor oil(HCO' 50) 70 Cremophor' EL 220 dl- a -tocopherol 60 (*not present in the final composition) Itraconazole was dissolved uniformly in a mixture of 85% phosphoric 30 acid, transcutol and ethanol, and other ingredients were added thereto and dissolved. Then, the resulting mixture was concentrated while heating at 55 C for 4 hrs to volatilize ethanol therefrom to obtain a viscous and transparent composition having no fluidity. The composition was filled into a hard capsule by the conventional method described in the General Preparation 35 Rule of Korea Pharmacopoeia.
WO 2005/023262 PCT/KR2004/002264 7 Example 2: Preparation of Soft Capsule A soft capsule was prepared using the following ingredients: Quantitv(mg/capsule) 5 Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 150 Polyoxyethylene-50-hydrogenated 10 castor oil(HCO' 50) 80 Cremophors EL 200 dl- a -tocopherol 60 (*not present in the final composition) The procedure of Example 1 was repeated using the above ingredients 15 to obtain a viscous and transparent composition having no fluidity. The composition was filled into a soft capsule by the conventional method described in the General Preparation Rule of Korea Pharmacopoeia. Example 3: Preparation of Hard Capsule -2) 20 A hard capsule was prepared by the procedure of Example 1 using the following ingredients: Quantitv(mg/capsule) 25 Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated 30 castor oil(HCO' 50) 200 Cremophore EL 80 dl- ca -tocopherol 60 (*not present in the final composition) 35 Example 4: Preparation of Hard Capsule -3) WO 2005/023262 PCT/KR2004/002264 8 A hard capsule was prepared by the procedure of Example 1 using the following ingredients: Ouantitv(mg/capsulel 5 Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated 10 castor oil(HCO ® 50) 200 Tween" 20 80 dl- ac -tocopherol 60 (*not present in the final composition) 15 Example 5: Preparation of Hard Capsule -4) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 20 Ouantitv(mg/capsule) Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 25 Polyoxyethylene-50-hydrogenated castor oil(HCO® 50) 150 Cremophor® EL 150 dl- a -tocopherol 60 (*not present in the final composition) 30 Example 6: Preparation of Hard Capsule -5) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 35 Quantitv(mg/capsule) WO 2005/023262 PCT/KR2004/002264 9 Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 5 Tween 20 200 Cremophor® EL 80 dl- a -tocopherol 60 (*not present in the final composition) 10 Example 7: Preparation of Hard Capsule -6) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 15 Quantity(m/capsule) Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 20 Tween® 20 150 Cremophor® EL 150 dl- ac -tocopherol 60 (*not present in the final composition) 25 Example 8: Preparation of Hard Capsule -7) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 30 Quantitv(mg/capsule) Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 35 Polyoxyethylene-50-hydrogenated castor oil(HCO® 50) 200 WO 2005/023262 PCT/KR2004/002264 10 Cremophore EL 80 dl- ca -tocopherol 120 (*not present in the final composition) 5 Example 9: Preparation of Hard Capsule -8) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 10 Quantity(mg/capsule) Itraconazole 50 Phosphoric acid 85% 150 Ethanol 300* Transcutol 83 15 Polyoxyethylene-50-hydrogenated castor oil(HCO® 50) 70 Cremophor ® EL 220 dl- a -tocopherol 60 (*not present in the final composition) 20 Example 10: Preparation of Hard Capsule -9) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 25 Ouantitv(mg/capsule) Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* 30 Dimethylisosorbide 83 Polyoxyethylene-50-hydrogenated castor oil(HCO® 50) 70 Cremophor® EL 220 dl- a -tocopherol 60 35 (*not present in the final composition) WO 2005/023262 PCT/KR2004/002264) 3 U 11 Example 11: Preparation of Hard Capsule -10) A hard capsule was prepared by the procedure of Example 1 using the following ingredients: 5 Ouantitv(mg/capsule) Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* 10 Glycofurol 83 Polyoxyethylene-50-hydrogenated castor oil(HCO® 50) 70 Cremophor ® EL 220 dl- ca -tocopherol 60 15 (*not present in the final composition) Example 12: Preparation of Hard Capsule -11) A hard capsule was prepared by the procedure of Example 1 using the 20 following ingredients: Quantitv(mg/capsule) Itraconazole 50 Hydrochloric acid 150 25 Ethanol 300* Dimethylisosorbide 83 Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 70 Cremophor' EL 220 30 dl- ac -tocopherol 60 (*not present in the final composition) Comparative Example: Preparation of Hard Capsule 35 A hard capsule was prepared by the procedure of Example 1, except WO 2005/023262 PCT/KR2004/002264 12 that the amphiphilic additive, transcutol, was not employed, using the following ingredients: Quantitv(mg/capsule) 5 Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 70 10 Cremophore EL 220 dl- a -tocopherol 60 (*not present in the final composition) Test Example 1: Dissolution Test 15 The dissolution rates of itraconazole were determined for the inventive preparation of Example 1; the preparation of Comparative Example; Sporanox® capsule; Sporanox® tablet; and Sporanox® liquid (Janssen Korea), in accordance with the dissolution test method II(paddle method) described in 20 the General Tests chapter of Korean Pharmacopoeia under the conditions listed below: Test apparatus: Erweka DT80(Erweka, Germany) Test solutions: 900 ml of artificial gastric juice(pH 1.2) 900 ml of phosphate buffer(pH 6.8) 25 Temperature of test solutions: 37 ± 0.5 Rotation speed: 100 ± 4 rpm Analytical method: liquid chromatography - column: Cosmosil C18(150 mm x 4.6 mm; Nacalai tesque, Japan) 30 - mobile phase: acetonitrile/phosphate buffer(pH 7.0) = 60:40 - flow rate: 1.2 ml/min. - detector: UV 255 nm - injection volume: 10 p1 35 The amount of dissolved itraconazole is represented by the cumulative amount of itraconazole eluted in 45 min. and the results are shown in Tables 1 WO 2005/023262 PCT/KR2004/002264 13 and 2. Table 1 Dissolution rates in artificial gastric juice(pH 1.2) Sample Examp Comparative Sporanox Sporanox' Sporanox ® le 1 Example capsule tablet liquid Dissolved amount 98.5% 53.2% 93.1% 98.3% (45min.) 99.7% 5 Table 2 Dissolution rates in phosphate buffer(pH 6.8) Sample Examp Comparative Sporanox ® Sporanox ® Sporanox' le 1 Example capsule tablet liquid Dissolved amount 96.3% 0.5% 0.5% 5.7% (45min.) 97.2% 93 As can be seen in Tables 1 and 2, the preparation of Example 1 exhibits higher amounts of itraconazole dissolved than those of Comparative Example 10 and the commercially available preparations at pH 1.2 or 6.8. In particular, the result shows that, in pH 6.8, the itraconazole dissolution rate of the preparation of Example 1 is remarkably enhanced as compared with the commercially available preparations. 15 Test Example 2: In Vivo Absorption Test In order to investigate the bioavailability of itraconazole contained in the inventive preparations, in vivo absorption tests were carried out as follows. Twenty 14 to 15 week-old male Sprague-Dawly rats each weighing 20 about 300 g were fasted for over 48 hours while they were allowed free access to water, and then divided into two groups of 10 each. Subsequently, for the test after food ingestion, ordinary solid feed and water were continuously supplied to the two groups of rats. The two groups of rats were orally administered with the inventive 25 preparation of Example 1 and the preparation of Comparative Example, respectively, at a dose of 20 mg itraconazole/kg body weight of the rat. Blood samples were taken directly from the hearts of the rats before the WO 2005/023262 PCT/KR2004/002264 14 administration and after 1, 2, 3, 4, 5, 7 and 24 hours from the administration, and the sera were separated therefrom. Added to 500 pl each of the serum samples were 50 p1 of an internal standard solution(methanol solution containing 500 tg/ml of nitrate econazole) 5 and 200 p l of 1 M carbonate buffer(Ph 10.0). 7 ml of an extraction solvent(n-heptane:isoamylalchol=9:1) was added thereto and the resulting mixture was shaken at 80 rpm for 5 min. to obtain an extract. The extract was centrifuged at 3,000 rpm for 10 min. and the solvent was evaporated at 50 "C under a nitrogen atmosphere. To the resulting residue was added 200 pl of 10 0.05% triethylamine solution of 65% aqueous acetonitrile and the mixture was subjected to HPLC under the following conditions. The observed results are shown in Table 3 and FIG. 1: - column: Inertsil ODS2(250 x 4.6 mm, 5 pm; GL science, Japan) - mobile phase: 65% aqueous acetonitrile solution 15 containing 0.05% triethylamine - detector: UV 258 nm - flow rate: 1.2 ml/min. - injection volume: 100 gl 20 Table 3
AUC
*1 Cmax * 2 Tmax* 3 AUCbefore ingestion (nghr/mt) (ng/m) (hr) /AUCaler ingestion (%) before Ex. 1 ingestion 5697.5±753.6 545.6±80.2 3.5±1.2 EI ingestion945 after iges 6023.7±732.5 583.5+75.6 3.6±1.1 ingestion before Comp. ingestion 4532±823.3 416.5±73.5 4.1±1.5 Comp. ingestion 61 Ex. after ingestion 5956.6±1023.1 535.6±82.6 3.8±1.9 -' -ingestion SArea under the curve of blood concentration till 48 hours *2 Maximum blood concentration *3 Time at the maximum blood concentration 25 The results in Table 3 and FIG. 1 show that bioavailability of itraconazole observed for the inventive preparation is far less influenced by WO 2005/023262 PCT/KR2004/002264 15 ingested food as compared to that of Comparative Example. While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and 5 changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Claims (11)
1. A viscous and glassy composition for oral administration comprising itraconazole, an acidifying agent, an amphiphilic additive, a surfactant and an 5 oil.
2. The composition of claim 1, wherein the itraconazole bioavailability ratio before and after food ingestion is 0.8 or higher. 10
3. The composition of claim 1, wherein the viscosity measured at 25 C is at least 10,000 cps.
4. The composition of claim 1 which has self-microemulsifying capability to form microemulsion particles when orally administered in the body fluid. 15
5. The composition of claim 1, wherein the itraconazole : acidifying agent : amphiphilic additive : surfactant : oil ratio by weight is in the range of 1 : 0.5~15 :0.5-20 : 0.5~15 : 0.5~15. 20
6. The composition of claim 1, wherein the acidifying agent is selected from the group consisting of phosphoric acid, hydrochloric acid and an aqueous solution thereof.
7. The composition of claim 1, wherein the amphiphilic is selected from the 25 group consisting of transcutol, dimethyl isosorbide, glycofurol, propylene glycol, propylene carbonate, solutol and a mixture thereof.
8. The composition of claim 1, wherein the surfactant is selected from the group consisting of polyoxyethylene glycolated natural or hydrogenated 30 vegetable oils, polyoxyethylene-sorbitan-fatty acid esters, polyoxyethylene fatty acid esters and a mixture thereof.
9. The composition of claim 1, wherein the oil is selected from the group consisting of tocopherol, a derivative thereof, and a mixture thereof. 35
10. A method of preparing the composition of claim 1 which comprises the WO 2005/023262 PCT/KR2004/002264 17 steps of: (a) dissolving itraconazole uniformly in a mixture of the acidifying agent, the amphiphilic additive and a volatile solvent, (b) further dissolving the surfactant and the oil in the resulting solution, and (c) removing the volatile solvent therefrom. 5
11. The method of claim 10, wherein the volatile solvent is a C 2 or C 3 alcohol. WO 2005/023262 PCT/KR2004/002264 1/1 FIG. 1 -m-Comp.Ex. 1(after ingestion) 600oo -- Comp.Ex. 1(before ingestion) -A- Ex. 1(after ingestion) S 500 (bfr 500 Ex. 1(before ingestion) 400 300 200 S 100 C.) ~~~0 P1 rIt 0 3 6 9 12 15 18 21 24 TIME (hrs)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0063147 | 2003-09-09 | ||
KR10-2003-0063147A KR100529766B1 (en) | 2003-09-09 | 2003-09-09 | Oral itraconazole composition which is not affected by ingested food and preparation thereof |
PCT/KR2004/002264 WO2005023262A1 (en) | 2003-09-09 | 2004-09-07 | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004270069A1 true AU2004270069A1 (en) | 2005-03-17 |
AU2004270069B2 AU2004270069B2 (en) | 2008-03-13 |
Family
ID=36096818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004270069A Ceased AU2004270069B2 (en) | 2003-09-09 | 2004-09-07 | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1663231A4 (en) |
JP (1) | JP2007505103A (en) |
KR (1) | KR100529766B1 (en) |
CN (1) | CN100475211C (en) |
AU (1) | AU2004270069B2 (en) |
BR (1) | BRPI0414192A (en) |
CA (1) | CA2538019C (en) |
IL (1) | IL173743A (en) |
MX (1) | MXPA06002239A (en) |
RU (1) | RU2006111477A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013192566A1 (en) | 2012-06-21 | 2013-12-27 | Mayne Pharma International Pty. Ltd. | Itraconazole compositions and dosage forms, and methods of using the same |
CN104688536B (en) * | 2015-02-03 | 2016-06-08 | 常州制药厂有限公司 | A kind of preparation method of itraconazole preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100336090B1 (en) * | 1998-06-27 | 2002-05-27 | 윤승원 | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
KR100435141B1 (en) * | 2000-12-28 | 2004-06-09 | 한미약품 주식회사 | Composition for oral administration of poorly soluble antifungal agent and process for the preparation thereof |
KR100455216B1 (en) * | 2001-06-27 | 2004-11-09 | 한미약품 주식회사 | Composition for oral administration of poorly soluble antifungal agent and process for the preparation thereof |
-
2003
- 2003-09-09 KR KR10-2003-0063147A patent/KR100529766B1/en not_active IP Right Cessation
-
2004
- 2004-09-07 CN CNB2004800258516A patent/CN100475211C/en not_active Expired - Fee Related
- 2004-09-07 EP EP04774524A patent/EP1663231A4/en not_active Withdrawn
- 2004-09-07 AU AU2004270069A patent/AU2004270069B2/en not_active Ceased
- 2004-09-07 CA CA002538019A patent/CA2538019C/en not_active Expired - Fee Related
- 2004-09-07 MX MXPA06002239A patent/MXPA06002239A/en not_active Application Discontinuation
- 2004-09-07 BR BRPI0414192-0A patent/BRPI0414192A/en not_active IP Right Cessation
- 2004-09-07 RU RU2006111477/15A patent/RU2006111477A/en not_active Application Discontinuation
- 2004-09-07 JP JP2006526025A patent/JP2007505103A/en active Pending
-
2006
- 2006-02-15 IL IL173743A patent/IL173743A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2006111477A (en) | 2006-08-27 |
JP2007505103A (en) | 2007-03-08 |
KR100529766B1 (en) | 2005-11-17 |
EP1663231A4 (en) | 2009-04-29 |
IL173743A (en) | 2012-08-30 |
CA2538019C (en) | 2009-09-01 |
AU2004270069B2 (en) | 2008-03-13 |
IL173743A0 (en) | 2006-07-05 |
BRPI0414192A (en) | 2006-10-31 |
CN1849123A (en) | 2006-10-18 |
CN100475211C (en) | 2009-04-08 |
MXPA06002239A (en) | 2006-06-20 |
KR20050026169A (en) | 2005-03-15 |
EP1663231A1 (en) | 2006-06-07 |
CA2538019A1 (en) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2376706C (en) | Antifungal oral composition containing itraconazole and process for preparing same | |
TWI490216B (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
RU2140291C1 (en) | Pharmaceutical composition for solubilization of poorly soluble active agent in composition-carrier and method of its making | |
EP1109532B1 (en) | Oral micro-emulsion composition of silybin | |
KR100425755B1 (en) | Compositions containing itraconazole and their preparation methods | |
KR101025641B1 (en) | Self-microemulsified mastic composition and capsule containing the composition | |
MXPA05001350A (en) | Pharmaceutical compositions comprising cyclosporin for oral administration. | |
EP0706380B1 (en) | Encapsulated medicine | |
MXPA05001352A (en) | Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant. | |
US20050058670A1 (en) | Oral itraconazole composition which is not affected by ingested food and process for preparing same | |
CA2538019C (en) | Oral itraconazole composition which is not affected by ingested food and process for preparing same | |
EP3854384A1 (en) | Pharmaceutical formulation comprising abiraterone acetate | |
JP2006509785A (en) | Oral microemulsion composition of biphenyldimethyldicarboxylic acid | |
NZ545768A (en) | Oral itraconazole composition which is not affected by ingested food and process for preparing same | |
CA2355271A1 (en) | Cyclosporin solution | |
KR100455216B1 (en) | Composition for oral administration of poorly soluble antifungal agent and process for the preparation thereof | |
KR101052947B1 (en) | Azelastine Liquid Formulation | |
KR20050098441A (en) | Rapid-acting emulsion concentration composition of artemisia extract and oral formulation thereof | |
KR20050121497A (en) | Pharmaceutical compositions and the methods of an oral preparation of itraconazole | |
JP2000355552A (en) | Oxatomide pharmaceutical preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |